RELIEF THERAPEUTICS HLDG - RLFTF STOCK NEWS

Relief Therapeutics Holding SA and NRx Pharmaceuticals have reached settlement agreements to resolve litigation. Within the next 30 days, NRx will transfer assets used in aviptadil development to Relief. Relief will gain exclusive rights to develop and commercialize aviptadil while continuing the Right to Try Program for two years. They will pay NRx milestone payments for successful product approvals and royalties up to $30 million based on sales. NRx will refrain from future competition in aviptadil development. The success of aviptadil commercialization is uncertain.

Relief Therapeutics Holding SA and NRx Pharmaceuticals, Inc. have extended the stay of their pending litigation until November 11, 2022. They are progressing in negotiations for a settlement; however, no final agreements have been reached, introducing uncertainty about the outcome.

Relief specializes in developing treatments for rare diseases, with products including PKU GOLIKE and ongoing projects like aviptadil and APR-TD011, which has FDA Orphan Drug Designation. The company is listed on the SIX Swiss Exchange under symbol RLF and OTCQB under RLFTF and RLFTD.

Relief Therapeutics, a Swiss biopharmaceutical company, has announced promising six-month stability data for a new formulation of RLF-100 (aviptadil) that shows high purity across various temperatures. This data supports the commercialization of RLF-100, which targets serious lung diseases like pulmonary sarcoidosis and ARDS. Relief plans to initiate a Phase 2b study in 2023 for pulmonary sarcoidosis. The company has also filed a provisional patent application for this formulation, underlining its potential clinical and commercial value.

Relief Therapeutics Holding SA (SIX:RLF, OTCQB:RLFTF, RLFTY) has announced an extension of its pending litigation settlement with NRx Pharmaceuticals, Inc. until November 7, 2022. This extension provides both parties additional time to finalize their tentative settlement agreement, although there are no guarantees of a successful conclusion. Relief is a biopharmaceutical company focused on developing treatments for rare diseases and has a diverse pipeline, including therapies for metabolic disorders and pulmonary indications.

Relief Therapeutics has filed Amendment No. 2 to its Form F-6 Registration Statement with the U.S. SEC to implement a reverse split of its American Depositary Receipts (ADRs), changing the ratio from 1:150 to 1:200. This change will take effect on November 3, 2022, as part of Relief's strategy to uplist its ADRs to the NASDAQ. The new ratio means that three new ADRs will be issued for every four existing ADRs. Relief aims to enhance accessibility for U.S. investors and maintain rights comparable to holders of ordinary shares.

Relief Therapeutics announced the promotion of Paolo Galfetti to Chief Operating Officer, effective October 14, 2022. Galfetti will maintain his role as CEO of APR Applied Pharma Research and continue his contributions to Relief's Board of Directors. With extensive experience in the pharmaceutical sector and a pivotal role in Relief's management since APR's acquisition, Galfetti is expected to enhance the company’s strategic initiatives, particularly the U.S. launch of PKU GOLIKE. Relief focuses on developing treatments for rare diseases, with significant ongoing projects including ACER-001 and aviptadil.

Relief Therapeutics has launched PKU GOLIKE in the U.S., a medical food for managing phenylketonuria (PKU). This launch, aided by an exclusive distributor, fulfills a milestone from the acquisition of APR Applied Pharma Research. Relief will make a milestone payment of CHF 2.8 million and issue 150 million shares, increasing its treasury by 200 million shares. Approximately 20,000 PKU patients in the U.S. require this dietary supplement for metabolic management. PKU GOLIKE offers improved patient compliance with its unique formulation, previously available in the E.U. since 2019.

Relief Therapeutics has appointed a leading national health services company as the exclusive distributor of PKU GOLIKE in the U.S. This product is a next-generation medical food developed for managing phenylketonuria (PKU) using patented Physiomimic™ technology, aimed at enhancing patient compliance. In 2023, the company plans to file for approval of APR-OD032, expanding its offerings for PKU treatment. The collaboration boosts the company's market approach and aims to improve patient access to innovative dietary solutions.

Relief Therapeutics has announced the initiation of an Investigator Initiated Trial for Nexodyn to address Epidermolysis Bullosa (EB), a rare skin condition affecting about 250,000 patients globally. The trial, approved by the IRB, will be led by Professor Amy Paller at a Chicago hospital, enrolling 15 participants over 12 weeks. This trial aims to evaluate the effectiveness of APR-TD011, a hypochlorous acid topical spray, in managing EB wounds. Positive outcomes could lead to FDA and EMA approvals, enhancing treatment options for EB patients.